e-learning
resources
Amsterdam 2011
Tuesday, 27.09.2011
Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Predictors of treatment outcome in multidrug-resistant tuberculosis
O. Oliveira, M. Villar, R. Duarte (Porto, Lisbon, Vila Nova de Gaia, Portugal)
Source:
Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
Session:
Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
Session type:
Poster Discussion
Number:
3296
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. Oliveira, M. Villar, R. Duarte (Porto, Lisbon, Vila Nova de Gaia, Portugal). Predictors of treatment outcome in multidrug-resistant tuberculosis. Eur Respir J 2011; 38: Suppl. 55, 3296
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Predictors of treatment outcome in multidrug-resistant tuberculosis in Portugal
Source: Eur Respir J 2013; 42: 1747-1749
Year: 2013
Evaluation of treatment outcomes for multidrug-resistant tuberculosis
Source: Eur Respir J 2001; 18: Suppl. 33, 312s
Year: 2001
Long-term treatment outcomes in multidrug-resistant tuberculosis (MDR-TB)
Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis
Year: 2007
Effect of fluoroquinolones on microbiologic outcome and survival in the treatment of multidrug-resistant tuberculosis
Source: Eur Respir J 2006; 28: Suppl. 50, 380s
Year: 2006
Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis
Source: Eur Respir J 2013; 41: 1393-1400
Year: 2013
Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB
Source: Eur Respir J 2009; 33: 1085-1094
Year: 2009
Recurrence after successful treatment among patients with multidrug-resistant tuberculosis
Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
Year: 2011
Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis
Source: Eur Respir J , 49 (3) 1601799; DOI: 10.1183/13993003.01799-2016
Year: 2017
Management and treatment of multidrug-resistant tuberculosis
Source: International Congress 2019 – Tuberculosis: latest advances and challenges in patient management
Year: 2019
Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid
Source: Eur Respir J 2015; 45: 1498-1501
Year: 2015
Management of multidrug-resistant tuberculosis and patients in retreatment
Source: Eur Respir J 2005; 25: 928-936
Year: 2005
Treatment outcome of multi-drug resistant tuberculosis
Source: Annual Congress 2004 - Problems of resistance and HIV coinfection in tuberculosis
Year: 2004
Long-term results of multidrug-resistant tuberculosis treatment.
Source: International Congress 2018 – Drug-resistant tuberculosis
Year: 2018
Treatment effectiveness and predictors of poor outcome in MDR-TB and XDR-TB
Source: Breathe 2008; 6: 161
Year: 2009
Multidrug-resistant tuberculosis: treatment outcome after 18 months of invidualised therapy
Source: Eur Respir J 2001; 18: Suppl. 33, 314s
Year: 2001
Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country
Source: Eur Respir J, 57 (6) 2002544; 10.1183/13993003.02544-2020
Year: 2021
Outcome of pulmonary multidrug-resistant tuberculosis
Source: Eur Respir J 2007; 30: Suppl. 51, 419s
Year: 2007
Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis
Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017
Year: 2017
Experience in the use of Bedakville in the therapy of multidrug-resistant tuberculosis and HIV infection.
Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept